Brokers Set Expectations for Krystal Biotech FY2025 Earnings

Key Points

• William Blair has lowered its FY2025 earnings per share (EPS) forecast for Krystal Biotech from $5.43 to $5.24, which is below the consensus estimate of $6.14.
• Krystal Biotech reported a quarterly EPS of $1.29, exceeding analysts' expectations of $1.08, with revenues of $96.04 million for the quarter.
• Analyst ratings for Krystal Biotech are mostly positive, with one hold, eight buy ratings, and a current consensus target price of $210.22.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - William Blair reduced their FY2025 earnings estimates for shares of Krystal Biotech in a note issued to investors on Monday, August 4th. William Blair analyst S. Corwin now forecasts that the company will earn $5.24 per share for the year, down from their prior forecast of $5.43. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q4 2025 earnings at $1.61 EPS.

Several other research firms also recently weighed in on KRYS. Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a research report on Friday, July 25th. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday. Finally, Bank of America dropped their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and a consensus target price of $210.22.

Krystal Biotech Trading Up 1.9%

Shares of KRYS traded up $2.56 during trading hours on Wednesday, reaching $138.66. The stock had a trading volume of 332,066 shares, compared to its average volume of 422,365. The firm has a 50-day simple moving average of $141.94 and a 200 day simple moving average of $155.36. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $207.84. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of 28.18 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in KRYS. Fifth Third Bancorp lifted its stake in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after buying an additional 432 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Krystal Biotech by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after buying an additional 23,934 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Krystal Biotech by 1.8% during the 4th quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock worth $2,044,000 after acquiring an additional 229 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in Krystal Biotech by 4.7% in the 4th quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock worth $4,875,000 after acquiring an additional 1,400 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 49,800 shares of company stock valued at $7,487,943 over the last three months. Corporate insiders own 13.70% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).